MR 107A 01
Alternative Names: MR-107A-01Latest Information Update: 02 Feb 2023
At a glance
- Originator Mylan
- Developer Viatris Inc
- Class Analgesics; Anti-inflammatories; Non-opioid analgesics; Nonsteroidal anti-inflammatories
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 02 Feb 2023 No development reported - Phase-II for Postoperative pain in USA (PO), before January 2023
- 22 Dec 2020 Mylan completes a phase II clinical trial in Postoperative pain in USA (PO) (NCT04571515)
- 01 Oct 2020 Mylan plans a phase II trial for postoperative pain in USA (NCT04571515)